CDT Equity Inc. Announces Reverse Stock Split
Rhea-AI Summary
CDT Equity (Nasdaq: CDT) announced a 1-for-25 reverse stock split effective March 26, 2026 at 5:00 pm ET, with shares expected to trade on a split-adjusted basis on Nasdaq at market open on March 27, 2026. As a result, every 25 issued and outstanding shares will combine into one share, reducing outstanding shares to approximately 4,722,450.
Par value remains $0.0001. Proportional adjustments apply to equity awards, convertible securities, warrants, and shares reserved under equity incentive plans. No fractional shares will be issued; cash payments will be made instead. The new CUSIP will be 20678X502.
Positive
- Outstanding shares reduced to approximately 4,722,450
- Reverse split effective March 26, 2026; trading adjusted on March 27, 2026
- Proportional adjustments to equity awards, convertible securities, and warrants
Negative
- No fractional shares issued; affected holders receive a cash payment instead
Key Figures
Market Reality Check
Peers on Argus
CDT was up 1.6% pre-announcement while peers were mixed: WINT down 9.91%, PPBT up 5.17%, PBM up 2.96%, SCNI slightly up, LIPO flat. Momentum scanner only flagged VRAX (+9.57%). This points to a stock-specific capital-structure event rather than a broad biotech move.
Previous Stock split Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 09 | Reverse stock split | Negative | -11.9% | Approved 1-for-8 reverse split, cutting outstanding shares to about 1.35M. |
| May 16 | Reverse stock split | Negative | -4.4% | Announced 1-for-15 reverse split, reducing outstanding shares to ~755,900. |
| Jan 23 | Reverse stock split | Negative | -20.0% | Announced 1-for-100 reverse split to address Nasdaq minimum bid requirement. |
All three prior reverse stock split announcements led to negative next-day moves, averaging -12.11%, suggesting a consistent pattern of weak price reaction to similar capital-structure changes.
Over the past year, CDT has repeatedly used reverse stock splits to manage its share structure and Nasdaq listing. Prior splits at ratios of 1-for-100, 1-for-15, and 1-for-8 each resulted in negative 24-hour moves of -20%, -4.41%, and -11.92%, respectively, for an average move of -12.11%. Today’s 1-for-25 reverse split continues this pattern of significant share consolidation and capital-structure adjustment.
Historical Comparison
In the past year, CDT announced 3 reverse stock splits, with an average next-day move of -12.11%. The new 1-for-25 split fits this ongoing pattern of aggressive share consolidation.
CDT has executed multiple reverse splits — previously 1-for-100, 1-for-15, and 1-for-8 — and now adds a 1-for-25 split, underscoring a continued reliance on share consolidation to manage listing and capital structure.
Regulatory & Risk Context
An effective S-3 shelf from 2026-01-29 registers 22,846,452 shares for resale by existing holders tied to consulting fees, an equity line, and a Corvus settlement. CDT does not receive proceeds from these resales, but the filing, together with a $25 million equity line and prior pre-funded warrant issuances, highlights significant potential dilution pressure alongside the new reverse split.
Market Pulse Summary
This announcement details a 1-for-25 reverse stock split, reducing outstanding shares to about 4,722,450 while keeping par value at $0.0001. CDT’s shares traded at 0.4938, near a 0.442 52-week low and far below the 6.77 200-day MA, showing prior weakness. Historically, similar reverse split news averaged a -12.11% move. Investors may watch how the effective S-3 registering 22,846,452 resale shares and the $25 million equity line interact with this latest consolidation.
Key Terms
reverse stock split financial
nasdaq capital market financial
cusip financial
equity awards financial
AI-generated analysis. Not financial advice.
NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”) announces that its board of directors has approved a 1-for-25 reverse stock split of the Company’s common stock. The Company’s stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios.
The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) at market open under the existing ticker symbol, “CDT” on March 27, 2026, the date which has been approved by Nasdaq for the effectiveness of such split.
As of the Effective Time, every 25 shares of the Company’s issued and outstanding common stock will be combined into one share of common stock. The par value per share of the Company’s common stock will remain unchanged at
The Company’s common stock will continue to trade on Nasdaq under the symbol “CDT” following the reverse stock split, with a new CUSIP number of 20678X502. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced to approximately 4,722,450. No fractional shares will be issued in connection with the reverse stock split, and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment.
The Company’s transfer agent, Continental Stock Transfer & Trust Co., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-reverse stock split shares of common stock electronically in book-entry form are not required to take any action to receive post-reverse stock split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.
About CDT Equity Inc.
CDT Equity Inc. (NASDAQ: CDT) is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. Originally established as Conduit Pharmaceuticals, the company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. Looking ahead, CDT are committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding CDT's future results of operations and financial position, CDT's business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to; the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of CDT's securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that CDT's product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that CDT may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties identified in other filings made by CDT with the U.S. Securities and Exchange Commission. Moreover, CDT operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond CDT's control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, CDT assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. CDT gives no assurance that it will achieve its expectations.
Investors
CDT Equity Inc.
Info@cdtequity.com
FAQ
What is the reverse stock split ratio for CDT (Nasdaq: CDT)?
When will CDT shares trade on a reverse split-adjusted basis on Nasdaq?
How many CDT shares will be outstanding after the reverse split?
Will CDT stockholders need to take action for the reverse split?
What happens to CDT fractional shares after the 1-for-25 split?
Will CDT's par value or ticker change after the reverse split?
